GlassScriptPhysician profile
Babu Makkena
NPI 1407042757
$18,291.05
in general payments reported to CMS, 2019-2025
42 companies · $4,977 in 2025
The $4,977 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $621 · 2021: $1,465 · 2022: $1,852 · 2023: $1,441 · 2024: $6,911 · 2025: $4,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Honoraria: $3,600 · Travel and Lodging: $69.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Honoraria | $3,600.00 |
| Travel and Lodging | $69.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $8,966.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $946.61 | 2019-2025 | |
| Abbott Laboratories | $918.24 | 2019-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Confirm Rx |
| Merck Sharp & Dohme LLC | $760.29 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $740.53 | 2019-2025 | Impella |
| Medtronic, INC. | $712.37 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Cobalt Dr Mri Surescan |
| Inari Medical, INC. | $534.11 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $444.28 | 2020-2025 | Lifevest |
| Pfizer INC. | $432.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $381.29 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $371.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.98 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $330.07 | 2019-2024 | Farxiga |
| Edwards Lifesciences Corporation | $310.64 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $303.72 | 2019-2023 | Repatha |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babu Makkena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.